Diabetes News

Preliminary results from an ongoing FDA investigation found no evidence that weight-loss drugs cause suicidal ideations and aspirations, although the agency said it cannot rule out a risk entirely.

Adults receiving semaglutide as a type 2 diabetes or obesity medication have a lower risk for suicidal ideation than those who are using a drug that is not a GLP-1 receptor agonist, according to findings published in Nature Medicine.

Providers can use continuous glucose monitoring metrics as well as HbA1c to assess diabetic retinopathy risk for adults with type 1 diabetes, according to findings published in Diabetes Technology & Therapeutics.

Once-weekly combination therapy of basal insulin icodec and semaglutide was noninferior to insulin glargine plus insulin aspart for lowering HbA1c among adults with type 2 diabetes, according to topline results from a phase 3a trial.

People with diabetes using a 15-day continuous glucose monitor sensor can now integrate their CGM with an automated insulin delivery system, according to a press release.

A form of inhaled insulin has been available for adults with type 1 and type 2 diabetes for nearly a decade, but providers say many people are not aware that it may be a treatment option for them.

Results showed a preoperative blood glucose level greater than 277 mg/dL in patients with diabetes and greater than 193 mg/dL in patients without diabetes was associated with an increased risk of infection after total hip arthroplasty.

Eli Lilly and Co. released an open letter stating its tirzepatide products should not be used for cosmetic weight loss and warning the public about the circulation of compounded and counterfeit tirzepatide.

Pregnant women are more likely to have high glucose levels if they report worse psychological stress before conception, according to study findings published in Journal of the Endocrine Society.

The SELECT trial, which showed semaglutide, a GLP-1 receptor agonist also approved for diabetes, reduced CV events in people with overweight/obesity and CVD but no diabetes, was one of the most important developments in cardiology in 2023.